Peritoneal cancer - Pipeline Insight, 2024

This “Peritoneal cancer- Pipeline Insight, 2024” report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Peritoneal cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Peritoneal cancer: Understanding

Peritoneal cancer: Overview

The invasion of the serous membrane lining the abdominal cavity, viscera, and coelom in amniotes by malignant cells is called peritoneal surface malignancy or peritoneal cancer (PC). It is divided into primary and secondary types. The de novo origin of cancer in the mesothelium of the abdomen causes primary mesothelioma. In contrast, the dissemination of tumor cells in the peritoneal cavity from other sites results in secondary peritoneal cancer.

Symptoms
Symptoms for primary peritoneal cancer can be very unclear and difficult to spot. Many of the symptoms are more likely to be caused by other medical conditions.

The symptoms of PPC include:

• a swollen tummy (abdomen)
• abdominal pain
• constipation or diarrhoea
• feeling or being sick
• feeling bloated
• loss of appetite

Diagnosis
? Obtaining a history regarding symptoms is frequently very helpful and this is followed by a physical exam. On physical examination, surgeon can sometimes feel tumor nodules in the abdomen or fluid (ascites).

? Imaging studies are helpful in evaluating patients who have symptoms suggestive of peritoneal carcinomatosis. Patients have either a CT scan or MRI of the abdomen and pelvis to confirm the presence of new or recurrent disease in the peritoneum. These imaging studies are done to assess the extent of disease in the abdomen. PET-CT can also be done to determine if disease has spread outside the abdominal cavity, such as the lungs.

? Laparoscopy is performed to confirm the diagnosis and determine if a patient is a candidate for cytoreductive surgery and HIPEC. Laparoscopy is a minimally invasive procedure where, through small incisions, samples of tumor (biopsies) are removed and sent to pathology to confirm a diagnosis.

Treatment
Surgery: It may be used to diagnose and treat peritoneum cancer if the place where the cancer first started to grow is unclear, or if you have a pelvic mass. This procedure is called exploratory surgery, during which the tumor is removed from the lining of the abdomen where the cancer has started to grow.

Chemotherapy: Chemotherapy uses anti-cancer drugs, which are usually injected into a vein. The drugs used for peritoneum cancer are similar to those anti-cancer drugs used for treating ovarian cancer. Depending on the type of chemotherapy drugs used, this treatment can be given weekly or every two to three weeks. In most cases, patients receive the treatment on an outpatient basis.

Targeted Therapy: Avastin® (bevacizumab) is one targeted therapy used to treat peritoneal cancer that has come back after other treatments (recurrent). It works by blocking the growth of blood vessels that feed tumors. Another type of targeted treatment, poly (ADP-ribose) polymerase inhibitors (PARP inhibitors), is used to block the repair mechanisms that occur during cell division. This helps slow or stop tumor growth. Currently approved PARP inhibitors include Lynparza® (olaparib), Rubraca® (rucaparib) and Zejula® (niraparib).

Peritoneal cancer- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peritoneal cancer pipeline landscape is provided which includes the disease overview and Peritoneal cancer treatment guidelines. The assessment part of the report embraces, in depth Peritoneal cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peritoneal cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Peritoneal cancer R&D. The therapies under development are focused on novel approaches to treat/improve Peritoneal cancer.

Peritoneal cancer Emerging Drugs Chapters

This segment of the Peritoneal cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Peritoneal cancer Emerging Drugs

Luvelta (STRO-002): Sutro Biopharma, Inc.

Luvelta (STRO-002) is a homogenous ADC, targeting folate receptor alpha, or FolRa (Conjugation of linker payload to 4 precisely positioned conjugatable non-natural amino acids), a Cathepsin B linker, which is a stable protease-cleavable linker (positioning of linker payloads allows for the cleaving of cathepsin b linker more efficiently, rapidly releasing cytotoxin that is accumulated in the tumor), and a hemiasterlin-derivative cytotoxic payload, with various mechanisms.

REFRaME-O1: A Phase II open-label study evaluating the efficacy and safety of luveltamab tazevibulin (STRO-002) in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1) is currently studied by the company.

IMGN151: ImmunoGen
IMGN151 is a next-generation ADC, designed to address the unmet needs of cancer patients with tumor types expressing lower levels of folate receptor alpha (FRa). IMGN151 comprises an asymmetric, bivalent, biparatopic antibody targeting two independent epitopes of FRa, linked to a highly potent maytansinoid derivative, DM21, via a cleavable peptide linker with enhanced stability, longer half-life, and increased bystander activity. It is currently investigated in Phase I trial for peritoneal cancer.

Catumaxomab: LintonPharm Co.,Ltd.

Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. It is a bispecific antibody that binds to EpCAM (the epithelial cell adhesion molecule) on the tumor cell--and CD3 on the T cell, recruits immune accessory cells through Fc?R binding at the same time. Catumaxomab kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models. Currently, Catumaxomab is being evaluated in clinical trials for advanced gastric cancer (NCT04222114) with peritoneal metastases in Phase III and non-muscle invasive bladder cancer (NCT04799847).

Peritoneal cancer: Therapeutic Assessment

This segment of the report provides insights about the different Peritoneal cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Peritoneal cancer

There are approx. 60+ key companies which are developing the therapies for Peritoneal cancer. The companies which have their Peritoneal cancer drug candidates in the most advanced stage, i.e. phase I include, Sutro Biopharma.

Phases

This report covers around 60+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Peritoneal cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peritoneal cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peritoneal cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peritoneal cancer drugs.

Peritoneal cancer Report Insights

• Peritoneal cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Peritoneal cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Peritoneal cancer drugs?
• How many Peritoneal cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peritoneal cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Peritoneal cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Peritoneal cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Shattuck Labs, Inc.
• Corcept Therapeutics
• Seagen
• Mersana Therapeutics
• IMPACT Therapeutics
• ImmunoGen
• LintonPharm Co.,Ltd.
• Sutro Biopharma, Inc.
• Elucida Oncology
• Bio-Path Holdings
• Clover Biopharmaceuticals AUS Pty Ltd
• Rhizen Pharmaceuticals SA
• Oncoinvent
• OncoMed Pharmaceuticals, Inc.
• Ipsen
• Green3Bio

Key Products

• OMP-305B83
• Relacorilant
• SL-172154
• tisotumab vedotin
• Upifitimab rilsodotin
• IMP4297
• IMGN151
• Catumaxomab
• Luvelta (STRO-002)
• ELU-001
• BP1001-A
• SCB-313
• RP12146
• Radspherin
• nanoliposomal irinotecan
• GRN-300

This product will be delivered within 1-3 business days.